tHEORetically speaking: How Accelerated Drug Development Requires Disruption in Market Access and Pricing

episode

tHEORetically Speaking not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from tHEORetically Speaking

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap 11 min · 13 Jul 2026

All episodes from tHEORetically Speaking →

Report any issue

Source

Recorded13 Oct 2022

Publisherfeeds.buzzsprout.com

Handlerec:11539565

Show notes

We recently sat down with Preeti Patel, MPharm, CEO and Founder of GPI, to learn what is driving the growing importance for early stage asset value and price prediction, how GPI is supporting clients through these challenges, and how this solution was developed.Global Pricing Innovations (GPI) is a price and access insights company that uses analytics to provide data-driven, evidence-based support, and helps clients make better investment decisions for drug development and commercialization. Read the full blog post here.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.